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Atherosclerosis is not only a lipid-driven disease but it is an intricate process that 
also involves the simultaneous and combined effect of inflammatory and immunologi-
cal factors. A substantial body of peer-reviewed studies has validated the cardiovascular 
risk predictive value of a variety of inflammatory markers including two members of 
the phospholipase A2 (PLA2) superfamily, the type IIA secretory PLA2 (sPLA2) and 
the lipoprotein-associated phospholipase A2 (Lp-PLA2). In animal, pathological and 
epidemiological studies, the increased levels of these two PLA2 have been related to 
an increase in complex coronary artery lesions and an increase in major cardiovas-
cular clinical events. Therefore, inhibition of these enzymes has become the focus of 
research in the last decennium. Novel pharmacological inhibitors of those enzymes 
emerge as promising therapeutical options for treating patients with coronary artery 
disease (CAD).
The type IIA secretory PLA2 (sPLA2) is a Ca2+-dependent enzyme expressed in 
hepatocytes, macrophages, platelets, and vascular smooth muscle cells. The catalytic 
function of this enzyme is related to the hydrolysis of the sn-2 acyl group of glycero-
phospholipids with further liberation of fatty acids and lysophospholipids, all playing 
an important role in the biosynthesis of lipid mediators such as platelet activating 
factor (PAF), leukotrienes, prostaglandins, and eicosanoids. Possible atherogenic 
mechanisms of sPLA2 include its effects on lipoproteins, which results in the release 
of various lipid mediators at the site of lipoprotein retention in the arterial wall that 
in turn may trigger local inflammatory cellular responses. Furthermore, in arterial 
tissue, sPLA2 may also directly modify LDL particles to become more atherogenic 
and may increase the affinity of apolipoprotein B-100 on LDL to glycosaminoglycans 
and proteoglycans. sPLA2 is also implicated in the production of isoprostanes which 
exhibit strong mitogenic activity and induce platelet aggregation and vasoconstriction. 
High sPLA2 concentrations may predict CAD events in patients with stable coronary 
artery disease and unstable angina, and all-cause mortality in patients with acute 
myocardial infarction. Raised sPLA2 concentration and activity is also associated 
with increased risk of incident CAD events in apparently healthy men and women. 
Recently it was also shown that sPLA2 mass and activity, may be predictive of second-
ary cardiovascular events in patients with CAD.
It is well established that substituted indoles, 6,7-benzoindoles and indolizines 
are potent inhibitors of sPLA2. Among them varespladib methyl (1-H-indole-3-
glyoxamide; A-002; Anthera Pharmaceuticals, San Mateo, CA) is an oral selective 
sPLA2 inhibitor. The effect of this inhibitor on enzyme concentration and on plasma 
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lipoproteins in patients with stable CAD was evaluated in the 
PLASMA (Phospholipase Levels and Serological Markers of 
Atherosclerosis) study, a Phase II, randomized, double-blind, 
placebo controlled parallel arm dose-response study. A total of 
393 patients were randomly assigned to receive either placebo 
(n=79) or one of four doses of A-002; 50 mg [n=79], 100 mg 
[n=80], 250 mg [n=78], or 500 mg [n=77] twice daily), for 8 
weeks. The primary endpoint was the change in sPLA2 con-
centration or activity from baseline to week 8. Mean sPLA2 
concentration fell by 86.7% in the overall active treatment 
group and by 48% in the placebo group (p <0·0001). The 
reductions in sPLA2 concentration in the A-002 groups were 
dose dependent (ranging from 69.2% in the 50 mg group to 
95.8% in the 500 mg group) and differed significantly from 
placebo (p <0.0001 for all doses). The results of this study 
show that A-002 reduces sPLA2 concentration in humans 
thus it might be an effective anti-atherosclerotic agent. The 
effect of this inhibitor on sPLA2 levels and other inflammatory 
markers of cardiovascular risk as well as on the incidence of 
myocardial injury is currently under investigation in clinical 
studies (PLASMA II, FRANCIS-ACS and SPIDER-PCI).
Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a 
calcium-independent PLA2 that is predominantly synthesized 
by macrophages. In plasma, Lp-PLA2 is bound to LDL and 
HDL lipoproteins, with a greater affinity for the polar surface 
of LDL particles, particularly small dense LDL. Lp-PLA2 
is produced and secreted by inflammatory cells involved in 
atherogenesis primarily monocyte-derived macrophages. Lp-
PLA2 rapidly degrades oxidatively modified phospholipids 
leading to formation of the proinflammatory and cytotoxic 
products lysophosphatidylcholine and oxidized free fatty acids. 
Lp-PLA2 staining in pathologic intimal thickening plaques 
is nearly absent; whereas in complex lesions such as thin-cap 
fibroatheromas and ruptured plaques, an intense Lp-PLA2 
expression within necrotic cores and surrounding macro-
phages including those in the fibrous cap is observed. This may 
imply that derived cytotoxic compounds from Lp-PLA2 play 
important role in plaque vulnerability. These observations, 
therefore, suggest that Lp-PLA2 inhibition may favorably 
affect rupture-prone lesions.
Many epidemiological studies have shown that increased 
concentrations of Lp-PLA2 predict future cardiovascular 
events. In a recent prospective, population-based survey of 
the epidemiology and pathogenesis of atherosclerosis (Bruneck 
study), the factors that influence plasma levels of Lp-PLA2 
and the prognostic value of this enzyme for cardiovascular dis-
ease were investigated. Subjects with incident cardiovascular 
disease (CVD) (cardiovascular death, myocardial infarction, 
stroke, and transient ischemic attack) had higher levels of 
Lp-PLA2 activity (884±196 versus 771±192 mmol/min/L, P 
<0.001). Increased Lp-PLA2 activity was significantly related 
to incident CVD [age- and sex-adjusted hazard ratio (95%CI) 
2.9 (1.6–5.5); third versus first tertile group; P <0.001] and with 
vascular mortality but not with non-CVD mortality.
Recent clinical studies have demonstrated that Lp-PLA2 
inhibition by azetidinones, a class of selective Lp-PLA2 inhibi-
tors that target the active-site serine residue of the enzyme, 
such as darapladib, may represent promising therapeutical 
options for treating patients with CVD. Darapladib [40, 80, 
and 160mg inhibits Lp-PLA2 activity approximately 43, 55, 
and 66% compared with placebo (P <0.001 at week 12). In 
the IBIS-2 (Integrated Biomarkers and Imaging Study-2) trial, 
a multicenter, randomized, double-blind, placebo-controlled 
study in 330 patients with angiographically confirmed CAD, 
darapladib halted the increase in the necrotic core volume 
compared with placebo without affecting total atheroma vol-
ume. Lp-PLA2 inhibition may represent a new approach for 
the treatment of atherosclerosis, however, the benefit of this 
intervention need to be established by on-going event-driven 
outcomes trials such as the STABILITY (Stabilization of 
Atherosclerotic Plaque by Initiation of Darapladib Therapy) 
trial.
S U G G E S T E D  B I B L I O G R A P H Y
 1. Anuurad E, Ozturk Z, Enkhmaa B, Pearson TA, Ber-
glund L. Association of lipoprotein-associated phospholipase 
A2 with coronary artery disease in African-Americans and Cau-
casians. J Clin Endocrinol Metab 2010 Mar 1. [Epub ahead 
of print]
 2. Dutour A, Achard V, Sell H, et al. Secretory type II phos-
pholipase A2 is produced and secreted by epicardial adipose tis-
sue and overexpressed in patients with coronary artery disease. 
J Clin Endocrinol Metab 2010; 95:963-967.
 3. Karakas M, Koenig W. Varespladib methyl, an oral phos-
pholipase A2 inhibitor for the potential treatment of 
coronary artery disease. I Drugs 2009; 12:585-592.
 4. Koenig W, Vossen CY, Mallat Z, Brenner H, Benessiano J, 
Rothenbacher D. Association between type II secretory 
phospholipase A2 plasma concentrations and activity and 
cardiovascular events in patients with coronary heart dis-
ease. Eur Heart J 2009; 30:2742-2748.
 5. McCullough PA. Darapladib and atherosclerotic plaque: 
should lipoprotein-associated phospholipase A2 be a 
therapeutic target? Curr Atheroscler Rep 2009; 11:334-
337.
 6. Garcia-Garcia HM, Serruys PW. Phospholipase A2 inhibi-
tors. Curr Opin Lipidol 2009; 20:327-332.
 7. Rosenson RS. Future role for selective phospholipase A2 
inhibitors in the prevention of atherosclerotic cardiovas-
cular disease. Cardiovasc Drugs Ther 2009; 23:93-101.
 8. Tsimikas S, Willeit J, Knoflach M, et al. Lipoprotein-associ-
ated phospholipase A2 activity, ferritin levels, metabolic 
syndrome, and 10-year cardiovascular and non-cardiovas-
cular mortality: results from the Bruneck study. Eur Heart 
J 2009; 30:107-115.
 9. Serruys PW, García-García HM, Buszman P, et al; Integrated 
SPLA2 AND LP-PLA2 AS BIOMARKERS OF CARDIOVASCULAR DISEASE AND THERAPEUTIC TARGETS
171
Biomarker and Imaging Study-2 Investigators. Effects of the 
direct lipoprotein-associated phospholipase A(2) inhibi-
tor darapladib on human coronary atherosclerotic plaque. 
Circulation 2008; 118:1172-1182.
 10. Mohler ER, Ballantyne CM, Davidson MH, et al, for the Dara-
pladib Investigators. The effect of darapladib on plasma lipo-
protein-associated phospholipase A2 activity and cardiovascu-
lar biomarkers in patients with stable coronary heart disease or 
coronary heart disease risk equivalent: the results of a multi-
center, randomized, double-blind, placebo-controlled study. J 
Am Coll Cardiol 2008; 51:1632-1641.
 11. Koenig W. Treating residual cardiovascular risk: will lipopro-
tein-associated phospholipase A2 inhibition live up to its prom-
ise? J Am Coll Cardiol 2008;51:1642–1644.
 12. PLASMA II trial: 
  http://clinicaltrials.gov/ct2/show/NCT00525954
 13. SPIDER-PCI trial: 
  http://clinicaltrials.gov/ct2/show/NCT00533039
 14. FRANCIS-ACS trial: 
  http://clinicaltrials.gov/ct2/show/NCT00743925
 15. STABILITY trial: http://www.vigour.ualberta.ca/nav02.
cfm?nav02=85287&nav01=58271 
